公开(公告)号：US20160175438A1

公开(公告)日：2016-06-23

申请号：US15058520

申请日：2016-03-02

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Lukas C. Amler ,  Mark C. Benyunes ,  Emma L. Clark ,  Christina H. de Toledo Pelizon ,  Zephania W. Kwong Glover ,  Lada Mitchell ,  Jayantha Ratnayake ,  Graham A. Ross ,  Ru-Amir Walker

IPC: A61K39/395 ,  A61K31/337 ,  A61K45/06 ,  C07K16/32

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.

Abstract translation: 本申请描述了一种同类别的HER2二聚抑制剂Pertuzumab的用途。 特别地，本申请描述了在HER2阳性乳腺癌患者群体中扩展无进展生存的方法; 结合两种HER2抗体治疗HER2阳性癌症而不增加心脏毒性; 并通过从相同的静脉内袋中共同施用Pertuzumab和曲妥珠单抗的混合物来治疗HER2阳性癌症。

公开(公告)号：US20130039909A1

公开(公告)日：2013-02-14

申请号：US13648085

申请日：2012-10-09

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Lukas C. Amler ,  Merrill Birkner ,  Chin-Yu Lin ,  Joachim Moecks ,  Andreas Strauss

IPC: A61K39/395 ,  C12Q1/68 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  B65B61/20 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57449 ,  G06Q99/00 ,  A61K2300/00

Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

公开(公告)号：US20150111211A1

公开(公告)日：2015-04-23

申请号：US14581196

申请日：2014-12-23

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC.

Inventor： Lukas C. Amler ,  Merrill Birkner ,  Chin-Yu Lin ,  Joachim Moecks ,  Andreas Strauss

IPC: C12Q1/68 ,  B65B61/20

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  B65B61/20 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57449 ,  G06Q99/00 ,  A61K2300/00

Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

Abstract translation: 本申请描述了使用低HER3作为治疗患有HER抑制剂的患者的选择标准，例如珀妥珠单抗。 它还描述了使用高HER2：HER3比例作为治疗癌症患者（如卵巢癌患者）的选择标准，其具有HER抑制剂如妥他珠单抗。 此外，本申请描述了使用高HER3作为治疗癌症患者与化疗剂例如吉西他滨的选择标准。

公开(公告)号：US20130095172A1

公开(公告)日：2013-04-18

申请号：US13649591

申请日：2012-10-11

Applicant: GENENTECH, INC.

Inventor： Sreedhara Alavattam ,  Lukas C. Amler ,  Mark C. Benyunes ,  Emma L. Clark ,  Christina H. de Toledo Pelizon ,  Zephania W. Kwong Glover ,  Lada Mitchell ,  Jayantha Ratnayake ,  Graham A. Ross ,  Ru-Amir Walker

IPC: A61K39/395 ,  A61P35/04 ,  A61P35/00 ,  C07K16/30 ,  A61K9/127

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.

Abstract translation: 本申请描述了包括Pertuzumab（一流的HER2二聚抑制剂）的用途和制品。 特别地，本申请描述了在HER2阳性乳腺癌患者群体中扩展无进展生存的方法; 结合两种HER2抗体治疗HER2阳性癌症而不增加心脏毒性; 治疗早期HER2阳性乳腺癌; 通过从相同的静脉内袋中共同施用Pertuzumab和曲妥珠单抗的混合物来治疗HER2阳性癌症; 治疗HER2阳性转移性胃癌; 用Pertuzumab，曲妥珠单抗和长春瑞滨治疗HER2阳性乳腺癌; 用Pertuzumab，曲妥珠单抗和芳香酶抑制剂治疗HER2阳性乳腺癌; 并治疗低HER3卵巢，原发性腹膜或输卵管癌。 它还描述了一种制造方法，其中包括其中具有Pertuzumab的小瓶和在其上提供安全性和/或功效数据的包装插页; 制造该制品的方法; 以及确保安全有效地使用与之相关的Pertuzumab的方法。 此外，本申请描述了一种静脉内（IV）袋，其中含有适用于给予癌症患者的Pertuzumab和曲妥珠单抗的稳定混合物。

公开(公告)号：US11021711B2

公开(公告)日：2021-06-01

申请号：US15838042

申请日：2017-12-11

Applicant: GENENTECH, Inc.

Inventor： Mark Lackner ,  Lukas C. Amler ,  Guy Cavet ,  Carol O'Brien ,  Ajay Pandita

IPC: C12Q1/6886 ,  C12N15/113 ,  A61K47/68

Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

公开(公告)号：US20180298387A1

公开(公告)日：2018-10-18

申请号：US15838042

申请日：2017-12-11

Applicant: GENENTECH, Inc.

Inventor： Mark Lackner ,  Lukas C. Amler ,  Guy Cavet ,  Carol O'Brien ,  Ajay Pandita

IPC: C12N15/113 ,  C12Q1/6886 ,  A61K47/68

Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

公开(公告)号：US08940302B2

公开(公告)日：2015-01-27

申请号：US13648085

申请日：2012-10-09

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Lukas C. Amler ,  Merrill Birkner ,  Chin-Yu Lin ,  Joachim Moecks ,  Andreas Strauss

IPC: A61K39/395

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  B65B61/20 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57449 ,  G06Q99/00 ,  A61K2300/00

Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

Abstract translation: 本申请描述了使用低HER3作为治疗患有HER抑制剂的患者的选择标准，例如珀妥珠单抗。 它还描述了使用高HER2：HER3比例作为治疗癌症患者（如卵巢癌患者）的选择标准，其具有HER抑制剂如妥他珠单抗。 此外，本申请描述了使用高HER3作为治疗癌症患者与化疗剂例如吉西他滨的选择标准。